

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

:Loria

Application No.

:09/225,499

Filed

:January 6, 1999

For

:5-ANDROSTENE-3 β ,17 α -DIOL AS AN INHIBITOR

OF TUMOR GROWTH

Examiner

:Goldberg, J.

Group Art Unit

:1614

TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing is a Response to Non-Final Office Action in response to the Office Action mailed March 26, 2003. Also enclosed are the following documents:

- (x) PTO Form 1449 (in duplicate) with cited reference attached
- (x) Certificate of First-Class Mail
- (x) Return postcard, postage prepaid
- (x) Additionally, please charge any fees due, or credit any overpayment to **Deposit Account No. 501536**. A duplicate of this transmittal is enclosed.

Βy

Please direct all correspondence to Customer No. 26,551.

Respectfully submitted,

Registration No. 43,524

Date

Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

(858) 587-9333

Customer No. 26,551

Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

Telephone: 858 587 9333



Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. 213.1C

Applicant(s) : Loria

Serial No. 09/225,499

For 5-ANDROSTENE-3β,17α-DIOL AS AN

INHIBITOR OF TUMOR GROWTH

Attorney Heather L. Callahan, Registration No. 43,524

Date of Deposit June 26, 2003

I hereby certify that the accompanying

Transmittal (in duplicate); Response to Non-Final Office Action dated March 26. 2003; PTO Form 1449 (in duplicate) with cited reference attached; and return postage prepaid postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, Mail Stop: Non-Fee Amendment.